Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: Contribution of immunogenicity studies in models

Infection and Immunity

Volumn 78, Issue 1, 2010, Pages 477-485

  Daher, Lena Juliette ^a,b   Demanga, Corine G ^a   Prieur, Eric ^a   Pérignon, Jean Louis ^a   Bouharoun Tayoun, Hasnaa ^b   Druilhe, Pierre ^a  

^a INSTITUT PASTEUR   (France)

^b LEBANESE UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 3; PARASITE ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIPARASITIC AGENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G3; MEMBRANE PROTEIN; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CELL ASSAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA FLANKING REGION; DRUG DESIGN; DRUG TARGETING; HELPER CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN FAMILY; TH1 CELL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGENICITY; CROSS REACTION; HUMAN; MULTIGENE FAMILY; PURIFICATION; SEQUENCE HOMOLOGY;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; B-LYMPHOCYTES; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MULTIGENE FAMILY; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SPLEEN; T-LYMPHOCYTES; VACCINES, SYNTHETIC; ADULT; AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; HUMANS; MEMBRANE PROTEINS;

EID: 73449110945     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00941-08     Document Type: Article

References (27)

1. Audran, R., M. Cachat, F. Lurati, S. Soe, O. Leroy, G. Corradin, P. Druilhe, and F. Spertini. 2005. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun. 73:8017-8026.
2. Bouharoun-Tayoun, H., P. Attanath, A. Sabchareon, T. Chongsuphajaisiddhi, and P. Druilhe. 1990. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro but act in cooperation with monocytes. J. Exp. Med. 172: 1633-1641.
3. Bouharoun-Tayoun, H., and P. Druilhe. 1992. Antibodies in falciparum malaria: what matters most, quantity or quality? Mem. Inst. Oswaldo Cruz 87(Suppl. 3):229-234.
4. Burgess, B. R., P. Schuck, and D. N. Garboczi. 2005. Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule. J. Biol. Chem. 280:37236-37245.
5. Demanga, C. G., L.-J. Daher, E. Prieur, C. Blanc, J.-L. Pérignon, H. Bouharoun-Tayoun, and P. Druilhe. 2010. Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans. Infect. Immun. 78:486-494.
6. Druilhe, P., and H. Bouharoun-Tayoun. 2002. Antibody-dependent cellular inhibition assay. Methods Mol. Med. 72:529-534.
7. Druilhe, P., F. Spertini, D. Soesoe, G. Corradin, P. Mejia, S. Singh, R. Audran, A. Bouzidi, C. Oeuvray, and C. Roussilhon. 2005. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2:e344.
8. Grey, H. M., J. W. Hirst, and M. Cohn. 1971. A new mouse immunoglobulin: IgG3. J. Exp. Med. 133:289-304.
9. Hermsen, C. C., D. F. Verhage, D. S. Telgt, K. Teelen, J. T. Bousema, M. Roestenberg, A. Bolad, K. Berzins, G. Corradin, O. Leroy, M. Theisen, and R. W. Sauerwein. 2007. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 25:2930-2940.
10. Huber, W., I. Felger, H. Matile, H. J. Lipps, S. Steiger, and H. P. Beck. 1997. Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3. Mol. Biochem. Parasitol. 87:231-234.
11. McColl, D. J., and R. F. Anders. 1997. Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol. Biochem. Parasitol. 90:21-31.
12. Mirano-Bascos, D., M. Tary-Lehmann, and S. J. Landry. 2008. Antigen structure influences helper T-cell epitope dominance in the human immune response to HIV envelope glycoprotein gp120. Eur. J. Immunol. 38:1231-1237.
13. Moorthy, V. S., M. F. Good, and A. V. Hill. 2004. Malaria vaccine developments. Lancet 363:150-156.
14. Mulhern, T. D., G. J. Howlett, G. E. Reid, R. J. Simpson, D. J. McColl, R. F. Anders, and R. S. Norton. 1995. Solution structure of a polypeptide containing four heptad repeat units from a merozoite surface antigen of Plasmodium falciparum. Biochemistry 34:3479-3491.
15. Nayak, B. P. 1999. Differential sensitivities of primary and secondary T-cell responses to antigen structure. FEBS Lett. 443:159-162.
16. Oeuvray, C., H. Bouharoun-Tayoun, H. Gras-Masse, E. Bottius, T. Kaidoh, M. Aikawa, M. C. Filgueira, A. Tartar, and P. Druilhe. 1994. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84:1594-1602.
17. Reichelt, P., C. Schwarz, and M. Donzeau. 2006. Single step protocol to purify recombinant proteins with low endotoxin contents. Protein Expr. Purif. 46:483-488.
18. Roggero, M. A., C. Servis, and G. Corradin. 1997. A simple and rapid procedure for the purification of synthetic polypeptides by a combination of affinity chromatography and methionine chemistry. FEBS Lett. 408:285-288.
19. Roussilhon, C., C. Oeuvray, C. Muller-Graf, A. Tall, C. Rogier, J. F. Trape, M. Theisen, A. Balde, J. L. Perignon, and P. Druilhe. 2007. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med. 4:e320.
20. Sabchareon, A., T. Burnouf, D. Ouattara, P. Attanath, H. Bouharoun-Tayoun, P. Chantavanich, C. Foucault, T. Chongsuphajaisiddhi, and P. Druilhe. 1991. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am. J. Trop. Med. Hyg. 45:297-308.
21. Singh, S., S. Soe, J. P. Mejia, C. Roussilhon, M. Theisen, G. Corradin, and P. Druilhe. 2004. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J. Infect. Dis. 190:1010-1018.
22. Singh, S., S. Soe, C. Roussilhon, G. Corradin, and P. Druilhe. 2005. Plasmodium falciparum merozoite surface protein 6 displays multiple targets for naturally occurring antibodies that mediate monocyte-dependent parasite killing. Infect. Immun. 73:1235-1238.
23. Singh, S., S. Soe, S. Weisman, J. W. Barnwell, J. L. Pérignon, and P. Druilhe. 2009. A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum. PLoS ONE 4:e5410.
24. Soe, S., M. Theisen, C. Roussilhon, K. S. Aye, and P. Druilhe. 2004. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect. Immun. 72:247-252.
25. + T-cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc. Natl. Acad. Sci. USA 98:4587-4592.
26. Theisen, M., S. Soe, K. Brunstedt, F. Follmann, L. Bredmose, H. Israelsen, S. M. Madsen, and P. Druilhe. 2004. A Plasmodium falciparum GLURPMSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine 22:1188-1198.
27. Theisen, M., J. Vuust, A. Gottschau, S. Jepsen, and B. Hogh. 1995. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. Clin. Diagn. Lab. Immunol. 2:30-34.